Viridian Therapeutics has received FDA approval for Lumvoa, a treatment for thyroid eye disease (TED), and has begun treating patients. The company is now focusing on successfully launching Lumvoa and leveraging its commercial infrastructure for both Lumvoa and its investigational drug elegrobart. This strategy aims to improve operational efficiency and franchise economics. While the current valuation is high with no near-term asset-based safety net, future profitability depends on effective commercialization, reimbursement, and expense management. The outlook remains positive but requires close monitoring of launch progress and financial stability.
Viridian Therapeutics and its recent FDA approval for Lumvoa provide context for health sector activity. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: Among 91 priced US health stocks tradable on Pluang, 59 rose and 31 fell today. Notable movers include Illumina, Inc. (ILMN) at USD 241.64 with a 1-day change of +5.55% and Pluang order activity of 97% Sell / 3% Buy, Ginkgo Bioworks Holdings Inc (DNA) at USD 7.44 with a 1-day change of +5.38%, and Citius Pharmaceuticals Inc (CTXR) at USD 0.58 with a 1-day change of +4.20% and Pluang order activity of 0% Sell / 100% Buy. Typical hold times on Pluang range from 11 to 86 days among these stocks.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
